Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: A meta-analysis

CMAJ. Canadian Medical Association Journal

Volumn 159, Issue 10, 1998, Pages 1245-1252

  Trindade, Evelinda ^a   Menon, Devidas ^b,c   Topfer, Leigh Ann ^b,c   Coloma, Carlos ^d  

^a Can Coord Off Hlth Technol A   (Canada)

^b Can Coord Off Hlth Technol A

^c Institute of Pharmaco Economics   (Canada)

^d Inter Univ Med Anthropol Res G   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; FLUVOXAMINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ANOREXIA; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG COST; FATIGUE; HEART PALPITATION; HUMAN; HYPOTENSION; INSOMNIA; META ANALYSIS; NAUSEA; RANDOMIZED CONTROLLED TRIAL; TREMOR; VERTIGO; VISUAL IMPAIRMENT; XEROSTOMIA;

EID: 0032542017     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: None     Document Type: Article

References (98)

1. US Agency for Health Care Policy and Research. Depression in primary care: vol 1. Detection, diagnosis, and treatment. Rockville (MD): The Agency; 1993. AHCPR publ no 93-0550.
2. US Agency for Health Care Policy and Research. Depression in primary care: vol 2. Treatment of major depression. Rockville (MD): The Agency; 1993. AHCPR publ no 93-0551.
3. Revicki DA, Brown RE, Keller MB, Gonzales J, Culpepper L, Hales RE. Cost-effectiveness of newer antidepressants compared with tricyclic antidepressants in managed care settings. J Clin Psychiatry 1997;58:47-58.
4. Jönsson B, Bebbington P. Economic studies of the treatment of depressive illness. In: Jönsson B, Rosenbaum J, editors. Health economics of depression. Chichester (UK): John Wiley & Sons; 1993. p. 35-48.
5. Hotopf M, Lewis G, Normand C. Are SSRIs a cost-effective alternative to tricyclics? Br J Psychiatry 1996;168;404-9.
6. Selective serotonin reuptake inhibitors (SSRIs) for major depression. Part I. Evaluation of the clinical literature. Ottawa: Canadian Coordinating Office for Health Technology Assessment; 1997. CCOHTA rep no 1997:3E.
7. Freemantle N, Long A, Mason J, Sheldon T, Song F, Watson P, et al. The treatment of depression in primary care: Which treatments are effective in the management of depression in primary care? Eff Health Care 1993;5:1-12.
8. Diagnostic and statistical manual of mental disorders: DSM-IV. 4th ed. Washington (DC): American Psychiatric Association; 1994.
9. Eddy DM, Hasselblad V. Fast*Pro software for meta-analysis. Boston: Academic Press; 1992.
10. Guy W. ECDEU assessment manual for psychopharmacology. Rev ed. Rockville (MD): National Institute for Mental Health; 1976.
11. Beasly CM, Sayler ME, Bosomworth JC, Wernicke JF. High-dose fluoxetine: efficacy and activating-sedating effects in agitated and retarded depression. J Clin Psychopharmacol 1991;11:166-74.
12. Teicher MH, Glod CA, Cole JO. Antidepressant drugs and the emergence of suicidal tendencies. Drug Safety 1993;8:186-212.
13. Freemantle N, House A, Song F, Mason JM, Sheldon TA. Prescribing selective serotonin reuptake inhibitors as strategy for prevention of suicide. BMJ 1994;309:249-53.
14. Light RJ, Pillemer DB. Summing up: the science of reviewing research. Cambridge (MA): Harvard University Press; 1984. p. 63-72.
15. Altamura AC, De Novellis F, Guercetti G, Invernizzi G, Percudani M, Montgomery SA. Fluoxetine compared with amitriptyline in elderly depression: a controlled clinical trial. Int J Clin Pharmacol Res 1989;9:391-6.
16. Amore M, Bellini M, Berardi D, Berlinzani L, Cervino G, Cremonini A, et al. Double-blind comparison of fluvoxamine and imipramine in depressed patients. Curr Ther Res 1989;46:815-20.
17. Arminen SL, Ikonen U, Pulkkinen P, Leinonen E, Mahlanen A, Koponen H, et al. A 12-week double-blind multi-centre study of paroxetine and imipramine in hospitalized depressed patients. Acta Psychiatr Scand 1994;89:382-9.
18. Bascara L. A double-blind study to compare the effectiveness and tolerability of paroxetine and amitriptyline in depressed patients. Acta Psychiatr Scand 1989; 80(Suppl 350):141-2.
19. Battegay R, Hager M, Rauchfleisch U. Double-blind comparative study of paroxetine and amitriptyline in depressed patients of a university psychiatric outpatient clinic (pilot study). Neuropsychobiology 1985;13:31-7.
20. Beasley CM, Holman SL, Potvin JH. Fluoxetine compared with imipramine in the treatment of inpatient depression: a multicenter trial. Ann Clin Psychiatry 1993;5:199-207.
21. Beasley CM, Sayler ME, Potvin JH. Fluoxetine versus amitriptyline in the treatment of major depression: a multicenter trial. Int Clin Psychopharmacol 1993;8:143-9.
22. Bersani G, Rapisarda V, Ciani N, Bertolino A, Sorge G. A double-blind comparative study of sertraline and amitriptyline in outpatients with major depressive episodes. Hum Psychopharmacol 1994;9:63-8.
23. Bignamini A, Rapisarda V, Italian Paroxetine Study Group. A double-blind multicentre study of paroxerine and amitriptyline in depressed outpatients. Int Clin Psychopharmacol 1992;6(Suppl 4):37-41.
24. Bowden CL, Schatzberg, AF, Rosenbaum A, Contreras SA, Samson JA, Dessain E, et al. Fluoxetine and desipramine in major depressive disorder. J Clin Psychopharmacol 1993;13:305-10.
25. Bramanti P, Ricci RM, Roncari R, Bilone F, Inga F, Teti V, et al. An Italian multicenter experience with fluvoxamine, a new antidepressant drug, versus imipramine. Curr Ther Res 1988;43:718-24.
26. Bremner JD. Fluoxetine in depressed patients: a comparison with imipramine. J Clin Psychiatry 1984;45:414-9.
27. Byerley WT, Reimherr FVV, Wood DR, Grosser BI. Fluoxetine, a selective serotonin uptake inhibitor, for the treatment of outpatients with major depression. J Clin Psychopharmacol 1988;8:112-5.
28. Byrne MM. Meta-analysis of early phase II studies with paroxetine in hospitalized depressed patients. Acta Psychiatr Scand 1989;80(Suppl 350):138-9.
29. Chouinard G. A double-blind controlled clinical trial of fluoxetine and amitriptyline in the treatment of outpatients with major depressive disorder. J Clin Psychiatry 1985;46(3 Sec 2):32-7.
30. Claghorn JL, Earl CQ, Walczak DD, Stoner KA, Wong LF, Kantner D, et al. Fluvoxamine maleate in the treatment of depression: a single-center, double-blind, placebo-controlled comparison with imipramine in outpatients. J Clin Psychopharmacol 1996;16:113-20.
31. Cohn CK, Shrivastava R, Mendels J, Cohn JB, Fahre LF, Claghorn JL, et al. Double-blind multicenter comparison of sertraline and amitriptyline in elderly depressed patients. J Clin Psychiatry 1990;51(Suppl B):28-33.
32. Cohn JB, Collins G, Ashbrook E, Wernicke JF. A comparison of fluoxetine, imipramine and placebo in patients with bipolar depressive disorder. Int Clin Psychopharmacol 1989;4:313-22.
33. Cohn JB, Wilcox C. A comparison of fluoxetine, imipramine, and placebo in patients with major depressive disorder. J Clin Psychiatry 1985;46(3 Sec 2):26-31.
34. Cohn JB, Wilcox CS. Paroxetine in major depression: a double-blind trial with imipramine and placebo. J Clin Psychiatry 1992;53(2 Suppl):52-6.
35. Coleman BS, Block BA. Fluvoxamine maleate, a serotonergic antidepressant; a comparison with chlorimipramine. Prog Neuropsychopharmacol Biol Psychiatry 1982;6:475-8.
36. Danish University Antidepressant Group. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord 1990;18:289-99.
37. De Jonghe F, Ravelli DP, Tuynman-Qua H. A randomized, double-blind study of fluoxerine and maprotiline in the treatment of major depression. Pharmacopsychiatry 1991;24:62-7.
38. De Jonghe F, Swinkels J, Tuynman-Qua H. Randomized double-blind study of fluvoxamine and maprotiline in treatment of depression. Pharmacopsychiatry 1991;24:21-7.
39. Dominguez RA, Goldstein BJ, Jacobson AF, Steinbook RM. A double-blind placebo-controlled study of fluvoxamine and imipramine in depression. J Clin Psychiatry 1985;46:84-7.
40. Doogan DP, Langdon CJ. A double-blind, placebo-controlled comparison of sertraline and dothiepin in the treatment of major depression in general practice. Int Clin Psychopharmacol 1994;9:95-100.
41. Dowling B, Webb MG, Halpin CM, Sangiwa MG. Fluoxetine: a comparative study with dothiepin. Ir J Psychiatry 1990;11:3-7.
42. Dunbar GC, Cohn JB, Fahre LF, Feighner JP, Fieve RR, Mendels J, et al. A comparison of paroxetine, imipramine and placebo in depressed outpatients. Br J Psychiatry 1991;159:394-8.
43. Dunner DL, Cohn JB, Walshe T, Cohn CK, Feighner JP, Fieve RR, et al. Two combined, multicenter double-blind studies of paroxetine and doxepin in geriatric patients with major depression. J Clin Psychiatry 1992;53(Suppl 2):57-60.
44. Fabre LF. A 6-week, double-blind trial of paroxetine, imipramine, and placebo in depressed outpatients. J Clin Psychiatry 1992;53(2 Suppl):40-3.
45. Fabre L, Birkhimer LJ, Zaborny BA, Wong LF, Kapik BM. Fluvoxamine versus imipramine and placebo: a double-blind comparison in depressed patients. Int Clin Psychopharmacol 1996;11:119-27.
46. Fabre LF, Scharf MB, Itil TM. Comparative efficacy and safety of nortriptyline and fluoxetine in the treatment of major depression: a clinical study. J Clin Psychiatry 1991;52(6 Suppl):62-7.
47. Fawcett J, Zajecka JM, Kravitz HM, Edwards J, Jeffriess H, Scorza E. Fluoxetine versus amitriptyline in adult outpatients with major depression. Curr Ther Res 1989;45:821-32.
48. Feighner JP. A comparative trial of fluoxetine and amitriptyline in patients with major depressive disorder. J Clin Psychiatry 1985;46:369-72.
49. Feighner JP, Boyer WF. Paroxetine in the treatment of depression: a comparison with imipramine and placebo. Acta Psychiatr Scand 1989;80(Suppl 350):125-9.
50. Feighner JP, Boyer WF, Merideth CH, Hendrickson GG. A double-blind comparison of fluoxetine, imipramine and placebo in outpatients with major depression. Int Clin Psychopharmacol 1989;4:127-34.
51. Feighner JP, Boyer WF, Meredith CH, Hendrickson GG. A placebo-controlled inpatient comparison of fluvoxamine maleate and imipramine in major depression. Int Clin Psychopharmacol 1989;4:239-44.
52. Feighner JP, Cohn JB. Double-blind comparative trials of fluoxetine and doxepin in geriatric patients with major depressive disorder. J Clin Psychiatr 1985; 46(3 Sec 2):20-5.
53. Feighner JP, Cohn JB, Fabre LF, Fieve RR, Mendels J, Shrivastava RK, et al. A study comparing paroxetine, placebo and imipramine in depressed patients. J Affect Disord 1993;28:71-9.
54. Gasperini M, Gatti F, Bellini L, Anniverno R, Smeraldi R. Perspectives in clinical psychopharmacology of amitriptyline and fluvoxamine: a double-blind study in depressed inpatients. Neuropsychobiology 1992;26:186-92.
55. Geretsegger C, Stuppaeck CH, Mair M, Platz T, Fartacek R, Heim M. Multicenter double blind study of paroxetine and amitryptyline in elderly depressed inpatients. Psychopharmacology 1995;119:277-81.
56. Ginestet D. Fluoxetine in endogenous depression and melancholia versus clomipramine. Int Clin Psychopharmacol 1989;4(Suppl 1):37-40.
57. Guelfi JD, Dreyfus JF, Pichot P. A double-blind controlled clinical trial comparing fluvoxamine with imipramine. Br J Clin Pharmacol 1983;15(Suppl 3):411S-417S.
58. Guillibert F, Pelicier Y, Archambault JC, Chabannes JP, Clerc G, Desvilles M, et al. A double-blind, multicentre study of paroxetine versus clomipramine in depressed elderly patients. Acta Psychiatr Scand 1989;80(Suppl 350):132-4.
59. Guy W, Wilson WH, Ban TA, King DL, Manov G, Fjetland OK. A double-blind clinical trial of fluvoxamine and imipramine in patients with primary depression. Psychopharmacol Bull 1984;20:73-8.
60. Harris B, Szulecka TK, Anstee JA. Fluvoxamine versus amitriptyline in depressed hospital out-patients: a multicentre, double-blind, comparative trial. Br J Clin Res 1991;2:89-99.
61. Hutchinson DR, Tong S, Moon CA, Vince M, Clarke A. Paroxetine in the treatment of elderly depressed patients in general practice: a double-blind comparison with amitriptyline. Int Clin Psychopharmacol 1992;6(Suppl 4):43-51.
62. Itil TM, Shrivastava RK, Mukherjee S, Coleman BS, Michael ST. A double-blind placebo-controlled study of fluvoxamine and imipramine in out-patients with primary depression. Br J Clin Pharmacol 1983;15(Suppl 3):433S-438S.
63. Judd FK, Moore K, Norman TR, Burrows GD, Gupta RK, Parker G. A multicentre double blind trial of fluoxetine versus amitriptyline in the treatment of depressive illness. Aust N Z J Psychiatry 1993;27:49-55.
64. Keegan D, Bowen RC, Blackshaw S, Saleh S, Dayal N, Remillard F, et al. A comparison of fluoxetine and amitriptyline in the treatment of major depression. Int Clin Psychopharmacol 1991;6:117-24.
65. Kuha S, Mehtonen OP, Henttonen A, Naaraìa M. The efficacy of fluoxetine versus maprotiline in depressed patients and by dose. Nord Psykiatr Tidskr 1991; 45:109-17.
66. Kuhs H, Rudolf GA. A double-blind study of the comparative antidepressant effect of paroxetine and amitriptyline. Acta Psychiatr Scand 1989;80(Suppl 350):145-6.
67. Laakmann G, Blaschke D, Engel R, Schwarz A. Fluoxetine vs amitriptyline in the treatment of depressed out-patients. Br J Psychiatry 1988;153(Suppl 3):64-8.
68. Lapierre YD, Browne M, Horn E, Oyewumi LK, Sarantidis D, Roberts N, et al. Treatment of major affective disorder with fluvoxamine. J Clin Psychiatry 1987;48:65-8.
69. Laursen AL, Mikkelsen PL, Rasmussen S, le Fèvre Honoré P. Paroxetine in the treatment of depression: a randomized comparison with amitriptyline. Acta Psychiatr Scand 1985;71:249-55.
70. Levine S, Deo R, Mahadevan K. A comparative trial of a new antidepressant, fluoxetine. Int Clin Psychopharmacol 1989;4(Suppl 1):41-5.
71. Lydiard RB, Laird LK, Morton WA, Steele TE, Kellner C, Laraia MT, et al. Fluvoxamine, imipramine, and placebo in the treatment of depressed outpatients: effects on depression. Psychopharmacol Bull 1989;25(1):68-70.
72. Möller HJ, Berzewski H, Eckmann F, Gonzalves N, Kissling W, Knorr W, et al. Double-blind multicenter study of paroxetine and amitriptyline in depressed inpatients. Pharmacopsychiatry 1993;26:75-8.
73. Moon CA, Jago W, Wood K, Doogan DP. A double-blind comparison of sertraline and clomipramine in the treatment of major depressive disorder and associated anxiety in general practice. J Psychopharmacol 1994;8:171-6.
74. Moon C, Vince M. Treatment of major depression in general practice: a double-blind comparison of paroxetine and lofepramine. Br J Clin Pract 1996;50:240-4.
75. Mullin JM, Pandita-Gunawardena VR, Whitehead AM. A double-blind comparison of fluvoxamine and dothiepin in the treatment of major affective disorder. Br J Clin Pract 1988;42:51-5.
76. Nathan RS, Perel JM, Pollock BG, Kupfer DJ. The role of neuropharmacologic selectivity in antidepressant action: fluvoxamine versus desipramine. J Clin Psychiatry 1990;51:367-72.
77. Nielsen BM, Behnke K, Arup P, Christiansen PE, Geisler A, Ipsen E, et al. A comparison of fluoxetine and imipramine in the treatment of outpatients with major depressive disorder. Acta Psychiatr Scand 1993;87:269-72.
78. Nielsen OA, Morsing I, Petersen JS, Larsen T, Moller SE, Manniche PM, et al. Paroxetine and imipramine treatment of depressive patients in a controlled multicentre study with plasma amino acid measurements. Acta Psychiatr Scand 1991;84:233-41.
79. Noguera R, Altuna R, Alvarez E, Ayuso JL, Casais L, Udina C. Fluoxetine vs. clomipramine in depressed patients: a controlled multicentre trial. J Affect Disord 1991;22:119-24.
80. Nolen WA, van de Putte JJ, Dijken WA, Kamp JS, Blansjaar BA, Kramer HJ, et al. Treatment strategy in depression: 1. Non-tricyclic and selective reuptake inhibitors in resistant depression: a double-blind partial crossover study on the effects of oxaprotiline and fluvoxamine. Acta Psychiatr Scand 1988; 78:668-75.
81. Norton KR, Sireling LI, Bhat AV, Rao B, Paykel ES. A double-blind comparison of fluvoxamine, imipramine and placebo in depressed patients. J Affect Disord 1984;7:297-308.
82. Ohrberg S, Christiansen PE, Severin B, Calberg H, Nilakantan B, Borup A, et al. Paroxetine and imipramine in the treatment of depressive patients in psychiatric practice. Acta Psychiatr Scand 1992;86:437-44.
83. Pélicier Y, Schaeffer P. Étude multicentrique en double aveugle comparant l'efficacité et la tolérance de la paroxétine et de la clomipramine dans la dépression réactionnelle du sujet âgé [A multi-centre, double-blind study to compare the efficacy and tolerability of paroxetine and clomipramine in elderly patients with reactive depression]. Encephale 1993;19:257-61.
84. Peselow ED, Filippi AM, Goodnick P, Barouche F, Fieve RR. The short-and long-term efficacy of paroxetine HCI: a. Data from a 6-week double-blind parallel design trial vs. imipramine and placebo. Psychopharmacol Bull 1989;25:267-71.
85. Poelinger W, Haber H. Fluoxetine 40mg vs maprotiline 75mg in the treatment of out-patients with depressive disorders. Int Clin Psychopharmacol 1989; 4(Suppl 1):47-50.
86. Reimherr FW, Byerley WF, Ward MF, Lebegue BJ, Wender PH. Sertraline, a selective inhibitor of serotonin uptake, for the treatment of outpatients with major depressive disorder. Psychopharmacol Bull 1988;24:200-5.
87. Reimherr FW, Chouinard G, Cohn CK, Cole JO, Itil TM, Lapierre YD, et al. Antidepressant efficacy of sertraline: a double-blind, placebo- and amitriptyline-controlled, multicenter comparison study in outpatients with major depression. J Clin Psychiatry 1990;51(12 Suppl B):18-27.
88. Remick RA, Claman J, Reesal R, Gibson RE, Agbayewa MO, Lam RW, et al. Comparison of fluoxetine and desipramine in depressed outpatients. Curr Ther Res 1993;53:457-65.
89. Remick RA, Keller FD, Gibson RE, Carter D. A comparison between fluoxetine and doxepin in depressed patients. Curr Ther Res 1989;46:842-8.
90. Remick RA, Reesal R, Oakander M, Allen J, Claman J, Ramirez CE, et al. Comparison of fluvoxamine and amitriptyline in depressed outpatients. Curr Ther Res 1994;55:243-50.
91. Robertson MM, Abou-Saleh MT, Harrison DA, Nairac BL, Edwards DR, Lock T, et al. A double-blind controlled comparison of fluoxetine and lofepramine in major depressive illness. J Psychopharmacol 1994;8:98-103.
92. Ropert R. Fluoxetine versus clomipramine in major depressive disorders. Int Clin Psychopharmacol 1989;4(Suppl 1):89-95.
93. Shrivastava RK, Shrivastava SH, Overweg N, Blumhardt CL. A double-blind comparison of paroxetine, imipramine, and placebo in major depression. J Clin Psychiatry 1992;53(2 Suppl):48-51.
94. South Wales Antidepressant Drug Trial Group. A double-blind multi-centre trial of fluoxetine and dothiepin in major depressive illness. Int Clin Psychopharmacol 1988;3:75-81.
95. Staner L, Kerkhofs M, Detroux D, Leyman S, Linkowski P, Mendlewicz J. Acute, subchronic and withdrawal sleep EEG changes during treatment with paroxetine and amitriptyline: a double-blind randomized trial in major depression. Sleep 1995;18:470-7.
96. Stark P, Hardison CD. A review of multicenter controlled studies of fluoxetine vs. imipramine and placebo in outpatients with major depressive disorder. J Clin Psychiatry 1985; 46(3 Sec 2):53-8.
97. Tamminen TT, Lehtinen VV. A double-blind parallel study to compare fluoxetine with doxepin in the treatment of major depressive disorders. Int Clin Psychopharmacol 1989;4(Suppl 1):51-6.
98. Young JP, Coleman A, Lader MH. A controlled comparison of fluoxetine and amitriptyline in depressed out-patients. Br J Psychiatry 1987;151:337-40.